Cancer Research Landon Prizes for Basic and Translational Cancer Research AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Samanta, A. K.
Right arrow Articles by Arlinghaus, R. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Samanta, A. K.
Right arrow Articles by Arlinghaus, R. B.
[Cancer Research 66, 6468-6472, July 1, 2006]
© 2006 American Association for Cancer Research

Priority Reports

Janus Kinase 2: A Critical Target in Chronic Myelogenous Leukemia

Ajoy K. Samanta1, Hui Lin1, Tong Sun1, Hagop Kantarjian2 and Ralph B. Arlinghaus1

Departments of 1 Molecular Pathology and 2 Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas

Requests for reprints: Ralph B. Arlinghaus, Department of Molecular Pathology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 712-792-8995; Fax: 713-794-1395; E-mail: rarlingh{at}mdanderson.org.

The Bcr-Abl tyrosine kinase is the causative factor in most chronic myelogenous leukemia (CML) patients. We have shown that Bcr-Abl is associated with a cluster of signaling proteins, including Janus kinase (Jak) 2, growth factor receptor binding protein 2–associated binder (Gab) 2, Akt, and glycogen synthase kinase (GSK)-3ß. Treatment of CML cell lines and mouse Bcr-Abl+ 32D cells with either Jak2 short interfering RNA or Jak2 kinase inhibitor AG490 inhibited pTyr Gab2 and pSer Akt formation, inhibited the activation of nuclear factor-{kappa}B, and caused the activation of GSK-3ß, leading to the reduction of c-Myc. Importantly, BaF3 cells expressing T315I and E255K imatinib-resistant mutants of Bcr-Abl underwent apoptosis on exposure to AG490 yet were resistant to imatinib. Similar to wild-type Bcr-Abl+ cells, inhibition of Jak2 by Ag490 treatment resulted in decrease of pSer Akt and c-Myc in imatinib-resistant cells. These results identify Jak2 as a potentially important therapeutic target for CML. (Cancer Res 2006; 66(13): 6468-72)




This article has been cited by other articles:


Home page
 Cancer Res.Home page
A. Ferrajoli, S. Faderl, Q. Van, P. Koch, D. Harris, Z. Liu, I. Hazan-Halevy, Y. Wang, H. M. Kantarjian, W. Priebe, et al.
WP1066 Disrupts Janus Kinase-2 and Induces Caspase-Dependent Apoptosis in Acute Myelogenous Leukemia Cells
Cancer Res., December 1, 2007; 67(23): 11291 - 11299.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. S. Chang, R. Santhanam, R. Trotta, P. Neviani, A. M. Eiring, E. Briercheck, M. Ronchetti, D. C. Roy, B. Calabretta, M. A. Caligiuri, et al.
High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBP{alpha}-driven myeloid differentiation
Blood, August 1, 2007; 110(3): 994 - 1003.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Saudemont, A. Hamrouni, P. Marchetti, J. Liu, N. Jouy, D. Hetuin, F. Colucci, and B. Quesnel
Dormant Tumor Cells Develop Cross-Resistance to Apoptosis Induced by CTLs or Imatinib Mesylate via Methylation of Suppressor of Cytokine Signaling 1
Cancer Res., May 1, 2007; 67(9): 4491 - 4498.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
M. Martinez-Moczygemba, D. P. Huston, and J. T. Lei
JAK kinases control IL-5 receptor ubiquitination, degradation, and internalization
J. Leukoc. Biol., April 1, 2007; 81(4): 1137 - 1148.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
R. A. Van Etten
Oncogenic signaling: new insights and controversies from chronic myeloid leukemia
J. Exp. Med., March 19, 2007; 204(3): 461 - 465.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y. Wang, D. Cai, C. Brendel, C. Barett, P. Erben, P. W. Manley, A. Hochhaus, A. Neubauer, and A. Burchert
Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation
Blood, March 1, 2007; 109(5): 2147 - 2155.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
F. J. Giles, J. Cortes, D. Jones, D. Bergstrom, H. Kantarjian, and S. J. Freedman
MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation
Blood, January 15, 2007; 109(2): 500 - 502.
[Abstract] [Full Text] [PDF]

Home page
 ASH ANNUAL MEETING ABSTRACTSHome page
A. K. Samanta, H. Lin, T. Sun, H. Kantarjian, and R. B. Arlinghaus
Jak2: A Potential Therapeutic Target for Chronic Myelogenous Leukemia (CML).
Blood (ASH Annual Meeting Abstracts), November 1, 2006; 108(11): 2121 - 2121.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.